Patients with mycoplasma pneumonia are infected with the causative agent Mycoplasma pneumoniae, resulting in a series of clinical features, and this infection is particularly common in preschool children, who can be treated with the macrolide antibiotic azithromycin for infection control. Azithromycin plays a major antibacterial role in the treatment of Mycoplasma pneumonia in children, but a series of adverse reactions can occur during the application of azithromycin, mainly gastrointestinal reactions are particularly common, as well as damage to liver and kidney function, abnormalities of the nervous system, etc. In the treatment of Mycoplasma pneumoniae infection in adults, moxifloxacin has gradually replaced azithromycin, which has a better antibacterial effect and is relatively less resistant to mycoplasma pneumoniae.